Kinase News and Research

RSS

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation.

3 Sep 2011

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

SWOG has selected four talented, early-career researchers for its 2011 Young Investigator Training Course. These four will attend a three-day workshop September 19 - 21 in Seattle, Wash., for intensive training in how to design and conduct cancer clinical trials.

3 Sep 2011

Researchers modify toxic chemical of marine cycyanobacteria to treat colon cancer

University of Florida researchers have modified a toxic chemical produced by tiny marine microbes and successfully deployed it against laboratory models of colon cancer.

2 Sep 2011

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.

2 Sep 2011

LCA applauds FDA approval of Xalkori for ALK positive non-small cell lung cancer

Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive. The drug was approved based on data from two clinical trials, both of which showed a significant increase in overall survival.

2 Sep 2011

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

Aeterna Zentaris Inc. today announced that a poster on its novel orally active anticancer Erk inhibitor, which includes AEZS-131, was presented at the 242nd American Chemical Society National Meeting held at the Colorado Convention Center in Denver, Colorado.

30 Aug 2011

Pfizer receives FDA approval of XALKORI for ALK-positive NSCLC

Pfizer Inc. has received FDA approval of XALKORI (crizotinib) capsules - the first and only therapy specifically for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

29 Aug 2011

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.

29 Aug 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

LUNGevity Foundation applauds FDA's recent approval of XALKORI lung cancer drug

LUNGevity Foundation applauds the US Food and Drug Administration's (FDA) recent approval of XALKORI (crizotinib) to treat lung cancer. The drug, introduced by Pfizer, Inc. showed such promise in early trials that it was given "fast track" status by the FDA.

29 Aug 2011

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Scientists define specific protein complex that allows cells to remove damaged mitochondria

In a joint research effort with researchers at St. Jude Children's Research Hospital, and with help from scientists at The University of Pennsylvania, The University of Minnesota, and the National Institutes of Health, investigators from the Florida campus of The Scripps Research Institute have defined a specific protein complex that allows cells to rid themselves of damaged mitochondria, which are the energy producing machines of the cell.

25 Aug 2011

Researchers reveal specific process by which HIV virus infects healthy T cells

A George Mason University researcher team has revealed the specific process by which the HIV virus infects healthy T cells-a process previously unknown. The principal investigator, HIV researcher Yuntao Wu, says he hopes this breakthrough will start a new line on inquiry into how researchers can use this knowledge to create drugs that could limit or halt HIV infection.

25 Aug 2011

Patients with liver disease may now access UCSD's new Nevada clinic

Patients in Nevada seeking care for liver disease may now access the university-level expertise of UC San Diego Health System's Center for Hepatobiliary Disease and Abdominal Transplantation.

25 Aug 2011

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

No effective treatment yet for acute lung injury

Patients can essentially drown in their own fluids when trauma and infection prompt blood vessels to leak, flooding millions of air sacs in their lungs.

22 Aug 2011

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.

18 Aug 2011

Syndax receives European patent allowance for entinostat to treat metastatic breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the European Patent Office for the patent application titled "N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL) - METHOXYCARBONYL - AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

18 Aug 2011

Drug SLM3 prevents multiplication of tumor cells

Tumors that do not respond to chemotherapy are the target of a cancer therapy that prevents the function of two enzymes in mouse tumor cells, according to Pennsylvania medical researchers.

17 Aug 2011

Kinase News and Research

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

Researchers modify toxic chemical of marine cycyanobacteria to treat colon cancer

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

LCA applauds FDA approval of Xalkori for ALK positive non-small cell lung cancer

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

Pfizer receives FDA approval of XALKORI for ALK-positive NSCLC

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

LUNGevity Foundation applauds FDA's recent approval of XALKORI lung cancer drug

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Scientists define specific protein complex that allows cells to remove damaged mitochondria

Researchers reveal specific process by which HIV virus infects healthy T cells

Patients with liver disease may now access UCSD's new Nevada clinic

Spinifex secures AU$6.25 million in expanded Series B funding

No effective treatment yet for acute lung injury

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Syndax receives European patent allowance for entinostat to treat metastatic breast cancer

Drug SLM3 prevents multiplication of tumor cells

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News